May 2026– date –
-
Amgen Advances MariTide Obesity Drug into Phase 3 MARITIME Program, Targeting Infrequent Dosing for Market Differentiation
Sahm Capital USA Overview Amgen has advanced maridebart cafraglutide (MariTide), its investigational obesity treatment, into the Phase 3 MARITIME development program. MariTide is an antibody-peptide conjugate designed with a dual mechani... -
CPHI Japan 2026 Highlights Technical Challenges in Peptide Development: GLP-1 Demand Drives Focus on Sustainable Manufacturing
AmbioPharm Japan Overview The CPHI Japan 2026 conference underscored the increasing complexity of peptide drug development and the rising technical expectations for CDMOs. Global demand for GLP-1 agonists is creating a significant bottle... -
Global and Korean Pharma Intensify Race for Next-Gen Oral Obesity Drugs: GLP-1/GIP Dual Agonists and Microneedle Patches Emerge
Chosun Biz South Korea Overview The 2026 European Congress on Obesity highlighted intensified global competition in next-generation oral obesity drug development. Viking Therapeutics announced positive Phase 2 results for its oral GLP-1/... -
siRNA Therapeutics: Advancements in Chemical Modification and Targeted Delivery Expand Clinical Horizons Beyond the Liver
MDPI Global Overview siRNA therapeutics are achieving significant clinical success driven by sophisticated chemical modifications and robust delivery systems. GalNAc conjugates have become the gold standard for liver-targeted therapies, ... -
Bora Group Acquires MacroGenics’ Manufacturing Operations, Expanding US Biopharmaceutical CDMO Platform
Manufacturing Chemist USA Overview Bora Group announced the acquisition of MacroGenics' GMP manufacturing and CDMO business for $122.5 million, which includes a biopharmaceutical drug substance manufacturing facility in Rockville, Maryla... -
Pharmaceutical Manufacturing Realignments Create Expansion Opportunities for CDMOs: GSK, BMS, Sanofi Divest Facilities
Pharmaceutical Technology USA Overview A significant reconfiguration is underway in the pharmaceutical manufacturing sector, with major CDMOs acquiring production facilities from pharmaceutical companies. Samsung Biologics, Rois, and Adr... -
OpenBind Launches First Open Dataset and AI Model to Enhance Drug-Target Interaction Prediction, Applied to EV-A71 Virus
University of Oxford UK Overview Researchers at the University of Oxford, as part of the OpenBind consortium, have released the first open dataset and predictive AI model specifically designed for drug discovery. This dataset comprises d... -
Isomorphic Labs Secures $2.1 Billion for AI Drug Discovery, Scaling AlphaFold-Driven Platform for Diverse Modalities
Pharmaceutical Technology UK Overview Isomorphic Labs, an Alphabet-backed AI drug discovery company, has closed a monumental $2.1 billion Series B funding round to accelerate its AI-driven drug development efforts. The investment will pr... -
Solid-State EV Battery Roadmaps Converge: Pilot Production in 2026, Consumer Availability Expected by Late 2027
EVドライブナビ Global Overview The year 2026 is marked as a period of intensified pilot production and trial integration for all-solid-state batteries (ASSBs), with consumer-ready ASSB EVs anticipated from late 2027 to 2028. Chinese manu... -
ProLogium Revolutionizes Solid-State Batteries with ‘All-Inorganic Super Flow’ Electrolyte, Achieves 5-Minute Fast Charge and Cost-Efficient Mass Production
owl - note Taiwan Overview Taiwan's ProLogium Technology is breaking through key barriers to solid-state battery commercialization with its proprietary 'All-Inorganic Super Flow' solid electrolyte technology. This innovation overcomes th...
